The cancer treatment developer, co-founded by researchers from University of Chicago, has secured funding in a round co-led by Arix Bioscience and RTW Investments.
Pyxis Oncology, a US-based cancer treatment developer utilising research from University of Chicago, has received $152m in a series B round featuring pharmaceutical firms Ipsen and Pfizer as well as pharmaceutical and chemical group Bayer.
Arix Bioscience and RTW Investments co-led the round, which was also backed by Perceptive Advisors, RA Capital Management, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Acuta Capital Partners, Ridgeback Capital Investments and Surveyor Capital.
The round was filled out…
